Intrinsiqq
Orgenesis Inc. logo

Orgenesis Inc. Quality Score

ORGS

⊜ Compare
Quality20

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
100/100
0.0x

Under 20x, reasonable relative to earnings

Not enough quarterly data
for a 1-year trend

Cash Flow Multiple
0/100
-0.0x

Negative FCF, no valuation support

Revenue Growth
0/100
-69.2%

Below 2%, essentially flat

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
100/100
-82.7%

Shrinking >2%, active buybacks

Margin Trend
0/100
-3795.0pp

Contracted >2pp, margin pressure

Capital Structure
0/100
$13M

Positive debt with no FCF to service it

2021
$5.00M
$6.00M
2022
$5.00M
$16.0M
2023
$837000
$20.0M
2024
$78000
$13.0M
CashDebt
Customize WeightsPremiumUpgrade

Orgenesis (ORGS) quality: score, margins and returns

Orgenesis (ORGS) scores 20/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 6 metrics each scored 0 to 100, on -3,842.3% operating margins. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Orgenesis (ORGS) a high-quality business?+

Orgenesis scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -3,842.3% operating margin. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Orgenesis's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from ORGS's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Orgenesis scores well and where it falls behind.

How profitable is Orgenesis?+

Orgenesis runs an operating margin of about -3,842.3% and a net margin of about -4,653.6%. Revenue has grown at roughly -23.3% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 26 Mar 2026, covering the period ending 31 Dec 2024, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ORGS

CompareIntrinsic value
TERNTerns Pharmaceuticals, Inc.
$0.01-8.89%10
STTKShattuck Labs Inc.
$5.29-3.38%40
RFLRafael Holdings Inc.
$1.07-0.93%40
IGCIGC Pharma Inc.
$0.20+5.26%26
SXTP60 Degrees Pharmaceuticals Inc.
$0.96-5.32%40
NEUPNeuphoria Therapeutics Inc.
$2.98-0.33%10
ALXOAlx Oncology Holdings Inc.
$1.36+5.43%10
LGVNLongeveron Inc.
$1.78+0.00%10

Spot a number that looks wrong? Check it in ORGS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ORGS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.